Category Archives: Population(s)

Suicidal ideation and associated factors among people living with HIV/AIDS in Ethiopia: A systematic review and meta-analysis

2024

Background Suicide is one of the main causes of mortality in the world, accounting for more fatalities than homicide, war, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), breast cancer, and...

Liver damage during treatment with reverse-transcriptase inhibitors in HIV patients

2024

The advent of highly active antiretroviral therapy (HAART) in 1996 has markedly enhanced the life expectancy of people living with HIV (PLWH), largely due to the effectiveness of reverse transcriptase...

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence

2024

BACKGROUND AND AIM: Human immunodeficiency virus (HIV) remains a significant global health challenge, with approximately 39 million people living with HIV worldwide as of 2022. Despite progress in antiretroviral therapy,...

Efficacy and tollerability of INI-based 2-drug regimen in virosuppressed persons living with HIV: A systematic review and meta-analysis

2024

BACKGROUND: The aim of this meta-analysis was to synthesize the available evidence from the literature on the efficacy and safety of integrase inhibitor-based two drug regimens compared to triple drug...

Retention in care among people living with HIV in Nigeria: A systematic review and meta-analysis

2024

BACKGROUND: In 2021, Nigeria had an estimated 1.9 million people living with the human immunodeficiency virus (PLHIV) and 1.7 million (90%) on antiretroviral therapy (ART). Study Design: A systematic review...

Burden of tuberculosis in underserved populations in South Africa: A systematic review and meta-analysis

2024

Identifying case-finding strategies to reduce tuberculosis (TB) incidence in high-burden countries requires better knowledge of the disease burden in key contributing populations and settings. To inform South Africa’s National Tuberculosis...

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis

2024

INTRODUCTION: Among many antiretroviral drugs, tenofovir alafenamide is used extensively in combination regimens of tenofovir/emtricitabine or tenofovir/emtricitabine/bictegravir. However, concerns have arisen about the potential of tenofovir alafenamide to exacerbate hyperlipidaemia....

A systematic review and meta-analysis of the impact of the COVID-19 pandemic on access to HIV pre-exposure prophylaxis: Lessons for future public health crises

2024

BACKGROUND: The World Health Organization is committed to strengthening access to pre-exposure prophylaxis (PrEP) for HIV prevention and its integration into primary care services. Unfortunately, the COVID-19 pandemic has disrupted...

Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: A systematic review and meta-analysis

2024

Background Despite significant reductions in mother-to-child HIV-1 transmission risks due to the advancements and scale-up of antiretroviral therapy (ART), the global burden of HIV-1 drug resistance (HIVDR) in treatment-naive and...

HIV prevention product acceptability and preference among women in Sub-Saharan Africa to inform novel biomedical options in development: A systematic review

2024

The availability of several HIV prevention options may allow women to choose a product that suits their lifestyle and preferences. Product attributes and contextual factors influence product acceptability, which affects...

Population pharmacokinetic simulations for dose optimization of tenofovir disoproxil fumarate in HIV-infected patients with moderate-to-severe renal impairment

2024

Tenofovir disoproxil fumarate (TDF) requires dosage adjustments from the standard 300 mg once daily to every 48–96 h for moderate-to-severe renal impairment to avoid excessive exposure. However, this extended interval...

Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir

2024

INTRODUCTION: Lenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!